Clinical Trials Logo

Toxemia clinical trials

View clinical trials related to Toxemia.

Filter by:

NCT ID: NCT06344819 Recruiting - Sepsis Clinical Trials

An Acupuncture Study for People At High Risk for Sepsis

Start date: March 20, 2024
Phase: Phase 2
Study type: Interventional

Researchers think acupuncture may improve outcomes for participants with sepsis, based on laboratory studies and previous studies in people with sepsis. The purpose of this study to see whether real acupuncture can improve outcomes for participants with sepsis when compared to sham acupuncture. Sham acupuncture is performed the same way as real acupuncture but will use different needles and target different sites or places on the body than real acupuncture.

NCT ID: NCT06338111 Completed - Biomarker Clinical Trials

Interventions Meant to Improve the Outcome of Critical Care Patients in the ED

Start date: November 9, 2020
Phase:
Study type: Observational

This study aims to identify the prognostic role of procalcitonin (PCT), soluble Triggering Receptor Expressed on Myeloid Cells-1 (sTREM-1), the soluble form of the urokinase plasminogen activator receptor (suPAR), highly sensitive C-reactive protein (hs-CRP), Interleukin-6 (IL-6), and azurocidin 1 (AZU1) in 28-day mortality for patients with sepsis in Emergency Department.

NCT ID: NCT06326385 Not yet recruiting - Sepsis Clinical Trials

Machine Learning Predictive Models for Sepsis Risk in ICU Patients With Intracerebral Hemorrhage

Start date: March 30, 2024
Phase:
Study type: Observational

Patients with intracerebral hemorrhage (ICH) in the intensive care unit (ICU) are at heightened risk of developing sepsis, significantly increasing mortality and healthcare burden. Currently, there is a lack of effective tools for the early prediction of sepsis in ICH patients within the ICU. This study aims to develop a reliable predictive model using machine learning techniques to assist clinicians in the early identification of patients at high risk and to facilitate timely intervention. The Medical Information Mart for Intensive Care (MIMIC) IV database (version 2.2) is an international online repository for critical care expertise. This database contains patient-related information collected from the ICUs of Beth Israel Deaconess Medical Center between 2008 and 2019. It includes a vast dataset of 299,712 hospital admissions and 73,181 intensive care unit patients. The eICU Collaborative Research Database (eICU-CRD) comprises data from over 200,000 ICU admissions for 139,367 unique patients across 208 US hospitals between 2014 and 2015, providing a valuable resource for critical care research. This study aims to establish and validate multiple machine learning models to predict the onset of sepsis in ICU patients with ICH and to identify the model with the optimal predictive performance.

NCT ID: NCT06323226 Recruiting - Sepsis Clinical Trials

The Impact of Sepsis on Long-term Outcomes in Critical Ill Children With Sepsis

Start date: January 1, 2019
Phase:
Study type: Observational

This study is conducted in critically ill children with sepsis with a five years follow-up. We aim to investigate the impact of sepsis on long-term outcomes including growth, neurodevelopment, survival rate, quality of life.

NCT ID: NCT06312488 Recruiting - Sepsis Clinical Trials

Point of Care Evaluation of Fibrinolysis in Sepsis

POCEFIS
Start date: January 22, 2024
Phase: N/A
Study type: Interventional

Impaired fibrinolysis in septic patients is associated with worse outcome. The present study investigates fibrinolysis shutdown in septic patients, defined as prolonged ClotPro® TPA lysis time at 30 minutes. The TPA lysis time reference range is established in a cohort of healthy volunteers.

NCT ID: NCT06307509 Not yet recruiting - Obesity Clinical Trials

Adiposity and Immunometabolism in Sepsis

AIMS
Start date: March 2024
Phase:
Study type: Observational

Obesity has been shown to increase adverse outcomes in some critically ill patients e.g. those with COVID-19. For patients with sepsis this association is less clear cut but there is evidence that body fat distribution, resulting from impaired subcutaneous adipose tissue function, is associated with adverse clinical outcomes in critical care. The investigators aim to study subcutaneous adipose tissue function in lean and obese sepsis patients in critical care and compare that to healthy controls. First, the study will investigate differences in adipose tissue function (inflammation and mitochondrial function) related to obesity. Second, the investigators will examine whether lean critically ill patients with sepsis have enhanced adipose tissue inflammation and mitochondrial dysfunction compared to lean controls and whether this is further exacerbated by obesity. Patients will be either undergoing emergency abdominal surgery, or will have been admitted to a critical care unit with a diagnosis of sepsis. The investigators will collect blood and adipose tissue biopsies from the patients, and these will be analysed for markers of inflammation and of mitochondrial function. The aim is to better understand the relationship between obesity, inflammation, mitochondrial dysfunction and sepsis. The investigators hope that this may improve the understanding of the pathophysiology of sepsis and allow more targeted interventions for patients based on differences in their baseline metabolic state.

NCT ID: NCT06305403 Not yet recruiting - Sepsis Clinical Trials

VEXUS and NGAL in the Diagnosis and Prognosis of Sepsis-associated Acute Kidney Injury

Start date: May 1, 2024
Phase:
Study type: Observational [Patient Registry]

In this prospective observational study, patients hospitalized in mixed intensive care unit, aged between 18 and 80, and diagnosed with sepsis and septic shock according to sepsis-3 criteria will be included. To determine whether patients develop AKI during the first five days of ICU admission, creatinine and urine output will be monitored daily for the first five days of ICU admission according to KDIGO criteria. Clinical diagnosis and treatment of AKI will be made according to KDIGO. According to KDIGO, patients will be divided into two groups: those who develop AKI and those who do not. By comparing plasma NGAL and VEXUS scores between groups, the sensitivity and specificity of the VEXUS score in determining AKI will be determined.

NCT ID: NCT06295393 Recruiting - Sepsis Clinical Trials

Renin Angiotensin Aldosterone System In Septic Kids

RISK
Start date: January 24, 2024
Phase:
Study type: Observational

Prospective observational cohort study; pediatric sepsis vs. healthy pediatric subjects and pediatric sepsis with acute kidney injury (AKI) vs without AKI. Blood samples and renal ultrasound will be collected on sequential days for septic subject and one time for the healthy patients. Enzyme-linked immunosorbent assays (ELISA) with be run on serum plasma to compare the renin-angiotensin-aldosterone system (RAAS) between groups.

NCT ID: NCT06289179 Not yet recruiting - Sepsis Clinical Trials

Thyroid and Cortisol Hormone Response to Sepsis

Start date: March 1, 2024
Phase:
Study type: Observational

Thyroid and cortisol hormone response to sepsis

NCT ID: NCT06287684 Recruiting - Sepsis Clinical Trials

Molecular Endotype-Specific Dynamics of Lung Endothelial Barrier Integrity in Sepsis

MENDSEP
Start date: September 13, 2023
Phase:
Study type: Observational [Patient Registry]

Sepsis is a complex syndrome that causes lethal organ dysfunction due to an abnormal host response to infection. No drug specifically targeting sepsis has been approved. The heterogeneity in sepsis pathophysiology hinders the identification of patients who would benefit, or be harmed, from specific therapeutic interventions. Recent clinical genomics studies have shown that sepsis patients can be stratified as molecular endotypes, or subclasses, with important clinical implications. Classifying sepsis patients as molecular endotypes revealed that a poor prognosis endotype was characterized by immunosuppression and septic shock. Against this backdrop, the study hypothesis is that a poor prognosis for sepsis is defined by a molecular endotype reflecting impaired innate immune and endothelial barrier integrity in the primary anatomical site of infection.